TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Pitavastatin Vs. Simvastatin (Following Up-Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
Brief Summary: The purpose of this study is to compare the efficacy and safety of pitavastatin with that of simvastatin.


Options:
A: Arm Label: Treatment sequence A, B; Type: EXPERIMENTAL; Interventions: Drug: pitavastatin, Drug: placebo | Arm Label: Treatment sequence B, A; Type: EXPERIMENTAL; Interventions: Drug: pitavastatin, Drug: placebo | Intervention Type: DRUG; Name: pitavastatin; Assigned to Arm(s): Treatment sequence A, B, Treatment sequence B, A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Treatment sequence A, B, Treatment sequence B, A
B: Arm Label: Pitavastatin 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Pravastatin 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin | Arm Label: Pitavastatin 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Pravastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin | Arm Label: Pitavastatin 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Pravastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin 1 mg, Pitavastatin 2 mg, Pitavastatin 4 mg | Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): Pravastatin 10 mg, Pravastatin 20 mg, Pravastatin 40 mg
C: Arm Label: Pitavastatin 4 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Pravastatin 40 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin 4 mg QD | Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): Pravastatin 40 mg QD
D: Arm Label: Pitavastatin 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Simvastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Arm Label: Pitavastatin 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Simvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin 2 mg, Pitavastatin 4 mg | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Simvastatin 20 mg, Simvastatin 40 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Self-Management on Improving Sleep Apnea Outcomes
Brief Summary: Obstructive sleep apnea syndrome (OSA) is a common sleep disorder that is associated with serious medical and psychological complications. Nasal continuous positive airway pressure (CPAP) is the treatment of choice for this condition because it is highly effective in reducing the frequency of nocturnal respiratory events, improving sleep architecture, decreasing daytime sleepiness and improving blood pressure. Incomplete patient adherence, however, limits the effectiveness of CPAP therapy and results in sub-optimal patient outcomes. Previous efforts to enhance CPAP adherence have resulted in only modest improvements, have generally not been theory-driven, and have had minimal effects on key patient outcomes such as reduction in OSA symptoms or increase in health-related quality of life (HRQOL). The planned intervention in this proposal, the Sleep Apnea Self-Management Program (SASMP), is based on the rationale that sleep apnea is a chronic disease that requires significant self-care on the part of the patient. We draw on the extensive chronic disease self-management literature to provide a solid theoretical justification for this pragmatic intervention both to better manage key aspects of OSA and to increase CPAP adherence. Chronic disease management programs help reduce symptoms, improve HRQOL, improve treatment adherence, and decrease medical utilization.


Options:
A: Arm Label: CPAP; Type: EXPERIMENTAL; Interventions: Device: CPAP, Other: Standard care for OSA | Arm Label: Standard care for OSA; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care for OSA | Intervention Type: DEVICE; Name: CPAP; Assigned to Arm(s): CPAP | Intervention Type: OTHER; Name: Standard care for OSA; Assigned to Arm(s): CPAP, Standard care for OSA
B: Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Self-Management; Type: EXPERIMENTAL; Interventions: Behavioral: Sleep Apnea Self-Management Program | Intervention Type: BEHAVIORAL; Name: Sleep Apnea Self-Management Program; Assigned to Arm(s): Self-Management | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care
C: Arm Label: MCI/OSA/CPAP Adherent; Type: EXPERIMENTAL; Interventions: Behavioral: CPAP adherence intervention | Arm Label: MCI/OSA/CPAP Non-adherent; Type: EXPERIMENTAL; Interventions: Behavioral: Attention control intervention | Intervention Type: BEHAVIORAL; Name: CPAP adherence intervention; Assigned to Arm(s): MCI/OSA/CPAP Adherent | Intervention Type: BEHAVIORAL; Name: Attention control intervention; Assigned to Arm(s): MCI/OSA/CPAP Non-adherent
D: Arm Label: Telemedicine Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto CPAP AirSense™ 10(Resmed) | Arm Label: Standard Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto CPAP AirSense™ 10(Resmed) | Intervention Type: DEVICE; Name: Auto CPAP AirSense™ 10(Resmed); Assigned to Arm(s): Standard Group, Telemedicine Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Double Blind Dose Ranging Study of Amphotericin B in Visceral Leishmaniasis
Brief Summary: This study is being conducted to assess the safety and efficacy of amphotericin B deoxycholate in doses of 0.75 mg/kg or 1.0 mg/kg for 15 doses. In each arm the drug is given in the conventional way every alternate day against the daily administration regimen being tested.


Options:
A: Intervention Type: DRUG; Name: Amphotericin B deoxycholate given as daily administration; Assigned to Arm(s): N/A
B: Arm Label: IL SSG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium Stibogluconate | Arm Label: ETC+MWT; Type: EXPERIMENTAL; Interventions: Procedure: Electro-thermo-coagulation, Drug: DAC N-055 | Arm Label: MWT; Type: EXPERIMENTAL; Interventions: Drug: DAC N-055 | Intervention Type: PROCEDURE; Name: Electro-thermo-coagulation; Assigned to Arm(s): ETC+MWT | Intervention Type: DRUG; Name: Sodium Stibogluconate; Assigned to Arm(s): IL SSG | Intervention Type: DRUG; Name: DAC N-055; Assigned to Arm(s): ETC+MWT, MWT
C: Intervention Type: DRUG; Name: Paromomycin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amphotericin B; Assigned to Arm(s): N/A
D: Arm Label: ETC + DAC N-055; Type: EXPERIMENTAL; Interventions: Other: Electro-thermo-coagulation, Drug: DAC N-055 | Arm Label: ETC + physiological saline; Type: ACTIVE_COMPARATOR; Interventions: Other: Electro-thermo-coagulation, Drug: saline | Intervention Type: OTHER; Name: Electro-thermo-coagulation; Assigned to Arm(s): ETC + DAC N-055, ETC + physiological saline | Intervention Type: DRUG; Name: DAC N-055; Assigned to Arm(s): ETC + DAC N-055 | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): ETC + physiological saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Double Blind Dose Ranging Study of Amphotericin B in Visceral Leishmaniasis
Brief Summary: This study is being conducted to assess the safety and efficacy of amphotericin B deoxycholate in doses of 0.75 mg/kg or 1.0 mg/kg for 15 doses. In each arm the drug is given in the conventional way every alternate day against the daily administration regimen being tested.


Options:
A: Arm Label: WR 279,396 Topical Treament; Type: EXPERIMENTAL; Interventions: Drug: WR 279,396 topical cream | Arm Label: Paromomycin Alone Topical treatment; Type: EXPERIMENTAL; Interventions: Drug: Paromomycin Alone topical cream | Arm Label: Vehicle Placebo Cream; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle placebo cream | Intervention Type: DRUG; Name: WR 279,396 topical cream; Assigned to Arm(s): WR 279,396 Topical Treament | Intervention Type: DRUG; Name: Paromomycin Alone topical cream; Assigned to Arm(s): Paromomycin Alone Topical treatment | Intervention Type: DRUG; Name: Vehicle placebo cream; Assigned to Arm(s): Vehicle Placebo Cream
B: Arm Label: Sodium stibogluconate intravenous; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium stibogluconate (Pentostam) | Arm Label: ThermoMed device; Type: EXPERIMENTAL; Interventions: Device: ThermoMed | Intervention Type: DRUG; Name: Sodium stibogluconate (Pentostam); Assigned to Arm(s): Sodium stibogluconate intravenous | Intervention Type: DEVICE; Name: ThermoMed; Assigned to Arm(s): ThermoMed device
C: Intervention Type: DRUG; Name: Amphotericin B deoxycholate given as daily administration; Assigned to Arm(s): N/A
D: Arm Label: WR 279,396; Type: EXPERIMENTAL; Interventions: Drug: WR 279,396 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: WR 279,396; Assigned to Arm(s): WR 279,396 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Part 1:Phase I Open-Label, Single-Center to Evaluate the Safety of a Commercially Available Adjuvanted Influenza Vaccine When Administered to Elderly Subjects Part 2: A Phase III, Randomized, Controlled, Observer-Blind, Single-Center Study to Evaluate the Immunogenicity and Safety of a Commercially Available Influenza Vaccine and a Conventional Commercially Available Influenza Vaccine When Administered to Elderly Subjects
Brief Summary: Clinical Trial in Two parts:

Part 1: Phase I, Open-Label, Single-Center Study to Evaluate the Safety of an adjuvanted Influenza Vaccine When Administered to Elderly Subjects.

Part 2: A Phase III, Randomized, Controlled, Observer-blind, Single-Center Study to Evaluate the Immunogenicity and Safety of an adjuvanted and a conventional Influenza Vaccine When Administered to Elderly Subjects.


Options:
A: Arm Label: FluNG Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Bio's influenza vaccine GSK2186877A | Arm Label: Fluarix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fluarix TM | Intervention Type: BIOLOGICAL; Name: GSK Bio's influenza vaccine GSK2186877A; Assigned to Arm(s): FluNG Group | Intervention Type: BIOLOGICAL; Name: Fluarix TM; Assigned to Arm(s): Fluarix Group
B: Intervention Type: BIOLOGICAL; Name: Influenza vaccine; Assigned to Arm(s): N/A
C: Arm Label: Influenza A (H5N1) 18-64Y Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo 18-64Y Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Influenza A (H5N1) >64Y Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo >64Y Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Influenza A (H5N1) Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Influenza A (H5N1) 18-60Y Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo 18-60Y Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Influenza A (H5N1) >60Y Group; Type: EXPERIMENTAL; Interventions: Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted | Arm Label: Placebo >60Y Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted; Assigned to Arm(s): Influenza A (H5N1) 18-60Y Group, Influenza A (H5N1) 18-64Y Group, Influenza A (H5N1) >60Y Group, Influenza A (H5N1) >64Y Group, Influenza A (H5N1) Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo 18-60Y Group, Placebo 18-64Y Group, Placebo >60Y Group, Placebo >64Y Group, Placebo Group
D: Intervention Type: BIOLOGICAL; Name: CAIV-T; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short Duration Exclusive Breastfeeding With Abrupt Weaning to Reduce the Risk of Mother-to-Child HIV Transmission
Brief Summary: The study is designed as a randomized, controlled trial with specific observational objectives. All HIV-seropositive pregnant subjects electing to breastfeed their child will be counselled to exclusively breastfeed through 4 months of age. All live-born children will be randomized (1:1) at birth to one of two counseling programs: A) to encourage abrupt weaning at 4 months of age, or B) to encourage exclusive breastfeeding through 6 months of age with the introduction of typical weaning foods ad lib.


Options:
A: Arm Label: Parenting Insight; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Parenting Insights | Arm Label: Child Safety Insights; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Child Safety Insights | Intervention Type: BEHAVIORAL; Name: Child Safety Insights; Assigned to Arm(s): Child Safety Insights | Intervention Type: BEHAVIORAL; Name: Parenting Insights; Assigned to Arm(s): Parenting Insight
B: Arm Label: Abrupt Weaning; Type: EXPERIMENTAL; Interventions: Other: abrupt weaning at 4 months | Arm Label: Exclusive breastfeeding per WHO guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: Continued exclusive breastfeeding | Intervention Type: OTHER; Name: abrupt weaning at 4 months; Assigned to Arm(s): Abrupt Weaning | Intervention Type: OTHER; Name: Continued exclusive breastfeeding; Assigned to Arm(s): Exclusive breastfeeding per WHO guidelines
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Infant Sleeping and Soothing | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Repeated Food Exposure | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Infant Sleeping and Soothing, Behavioral: Repeated Food Exposure | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Infant Sleeping and Soothing; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: Repeated Food Exposure; Assigned to Arm(s): 2, 3
D: Arm Label: Doula; Type: EXPERIMENTAL; Interventions: Behavioral: Doula | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Doula; Assigned to Arm(s): Doula

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short Duration Exclusive Breastfeeding With Abrupt Weaning to Reduce the Risk of Mother-to-Child HIV Transmission
Brief Summary: The study is designed as a randomized, controlled trial with specific observational objectives. All HIV-seropositive pregnant subjects electing to breastfeed their child will be counselled to exclusively breastfeed through 4 months of age. All live-born children will be randomized (1:1) at birth to one of two counseling programs: A) to encourage abrupt weaning at 4 months of age, or B) to encourage exclusive breastfeeding through 6 months of age with the introduction of typical weaning foods ad lib.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine and mulitvitamins | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine and mulitvitamins | Intervention Type: DRUG; Name: Nevirapine and mulitvitamins; Assigned to Arm(s): 1, 2
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine, Drug: AZT, Drug: NVP and AZT | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: AZT, Drug: NVP+AZT | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: NVP | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: AZT; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: NVP and AZT; Assigned to Arm(s): A | Intervention Type: DRUG; Name: NVP; Assigned to Arm(s): B | Intervention Type: DRUG; Name: NVP+AZT; Assigned to Arm(s): C
C: Arm Label: Abrupt Weaning; Type: EXPERIMENTAL; Interventions: Other: abrupt weaning at 4 months | Arm Label: Exclusive breastfeeding per WHO guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: Continued exclusive breastfeeding | Intervention Type: OTHER; Name: abrupt weaning at 4 months; Assigned to Arm(s): Abrupt Weaning | Intervention Type: OTHER; Name: Continued exclusive breastfeeding; Assigned to Arm(s): Exclusive breastfeeding per WHO guidelines
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nevirapine placebo | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nevirapine placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short Duration Exclusive Breastfeeding With Abrupt Weaning to Reduce the Risk of Mother-to-Child HIV Transmission
Brief Summary: The study is designed as a randomized, controlled trial with specific observational objectives. All HIV-seropositive pregnant subjects electing to breastfeed their child will be counselled to exclusively breastfeed through 4 months of age. All live-born children will be randomized (1:1) at birth to one of two counseling programs: A) to encourage abrupt weaning at 4 months of age, or B) to encourage exclusive breastfeeding through 6 months of age with the introduction of typical weaning foods ad lib.


Options:
A: Arm Label: maternal nevirapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: maternal placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: No intervention | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): maternal nevirapine | Intervention Type: DRUG; Name: No intervention; Assigned to Arm(s): maternal placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nevirapine placebo | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nevirapine placebo; Assigned to Arm(s): 2
C: Arm Label: Abrupt Weaning; Type: EXPERIMENTAL; Interventions: Other: abrupt weaning at 4 months | Arm Label: Exclusive breastfeeding per WHO guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: Continued exclusive breastfeeding | Intervention Type: OTHER; Name: abrupt weaning at 4 months; Assigned to Arm(s): Abrupt Weaning | Intervention Type: OTHER; Name: Continued exclusive breastfeeding; Assigned to Arm(s): Exclusive breastfeeding per WHO guidelines
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: HIV immune globulin solution | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: HIV immune globulin solution; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Arterial Hypertension Associated With Sickle Cell Disease
Brief Summary: The study will assess the effect of bosentan on pulmonary vascular resistance and exercise capacity in sickle cell disease (SCD) patients diagnosed with pulmonary arterial hypertension. It consists of 3 phases: Screening, Treatment and Follow-up. During the Screening visit, the study doctor will decide if patients meet the study requirements. All potential patients will have a diagnosis of increased pulmonary artery pressures that is shown by right heart catheterization conducted shortly prior to start of study treatment. Patients will be asked to perform exercise capacity test (walking as far as possible for 6 minutes). Following the Baseline visit, the treatment phase consists of 4 additional clinic visits during which the good and bad effects of the drug are reviewed and exercise capacity test will be repeated. Patients will be treated for 16 weeks. Blood samples will be collected every month, or more often, if needed. At the end of the study, patients will be asked to repeat the right heart catheterization and exercise capacity test. After completion of the study, patients will have the option of enrolling in a long-term follow-up study where all patients will receive active drug. Patients electing not to participate in the extension study will be followed up for safety assessments for about 28 days after the end of the study treatment.


Options:
A: Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): 2
C: Arm Label: Inhaled treprostinil; Type: EXPERIMENTAL; Interventions: Drug: Inhaled treprostinil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo inhalation solution | Intervention Type: DRUG; Name: Inhaled treprostinil; Assigned to Arm(s): Inhaled treprostinil | Intervention Type: DRUG; Name: Placebo inhalation solution; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Ambrisentan; Assigned to Arm(s): N/A

Answer: B